(NASDAQ: TPST) Tempest Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.73%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.6%.
Tempest Therapeutics's earnings in 2025 is -$41,843,000.On average, 3 Wall Street analysts forecast TPST's earnings for 2025 to be -$660,464,219, with the lowest TPST earnings forecast at -$928,593,316, and the highest TPST earnings forecast at -$473,168,192. On average, 2 Wall Street analysts forecast TPST's earnings for 2026 to be -$955,210,192, with the lowest TPST earnings forecast at -$1,177,009,914, and the highest TPST earnings forecast at -$733,410,470.
In 2027, TPST is forecast to generate -$987,739,909 in earnings, with the lowest earnings forecast at -$987,739,909 and the highest earnings forecast at -$987,739,909.